Physician profile
Suphithay A Anders
NPI 1558401919
$1,646.82
in general payments reported to CMS, 2019-2025
25 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $226 · 2021: $286 · 2022: $286 · 2023: $169 · 2024: $94.29 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.99 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.51 | 2020-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Exeltis, USA INC. | $147.97 | 2020-2025 | Slynd |
| Intuitive Surgical, INC. | $136.25 | 2021 | |
| Duchesnay USA Incorporated | $118.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.62 | 2019-2023 | |
| Biogen, INC. | $86.83 | 2025 | Zurzuvae |
| Allergan, INC. | $85.12 | 2019-2020 | |
| Organon LLC | $83.03 | 2022-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $80.42 | 2020-2025 | Myosure Tissue Removal Device, Aptima |
| Therapeuticsmd, INC. | $76.97 | 2019-2022 | |
| Astellas Pharma US INC | $76.51 | 2025 | Veozah |
| Evofem Biosciences, INC. | $48.45 | 2022 | |
| Valencia Technologies Corporation | $37.90 | 2025 | Ecoin Device Kit |
| Merck Sharp & Dohme LLC | $34.94 | 2022-2023 | Gardasil 9 |
| Coopersurgical, INC. | $27.58 | 2021-2024 | Summit Doppler |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $20.23 | 2025 | Airseal |
| Agile Therapeutics, INC. | $18.67 | 2021 | |
| Mayne Pharma Commercial LLC | $17.65 | 2021 | |
| Pfizer INC. | $17.44 | 2023 | |
| Dexcom, INC. | $17.20 | 2025 | Dexcom G6 Transmitter |
| Ethicon US, LLC | $16.76 | 2025 | Enseal X1, Harmonic |
| Sumitomo Pharma America, INC. | $15.36 | 2025 | Myfembree |
| Lupin INC. | $11.59 | 2020 | |
| Covidien Lp | $11.42 | 2019 | |
| Zyla Life Sciences, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suphithay Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.